Neuroprotective effects of donepezil against Aβ42-induced neuronal toxicity are mediated through not only enhancing PP2A activity but also regulating GSK-3β and nAChRs activity

Journal of Neurochemistry

Volumn 127, Issue 4, 2013, Pages 562-574

  Noh, Min Young ^a   Koh, Seong H ^a   Kim, Sung Min ^b   Maurice, Tangui ^c   Ku, Sae Kwang ^d   Kim, Seung H ^a  

^a Hanyang University   (South Korea)

^b Seoul National University   (South Korea)

^c University of Montpellier   (France)

^d Daegu Haany University   (South Korea)

Author keywords

amyloid beta; donepezil; GSK 3 ; nAChRs; neuroprotection; PP2A

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CHOLINESTERASE INHIBITOR; DONEPEZIL; GLYCOGEN SYNTHESIS KINASE 3BETA; NICOTINIC RECEPTOR; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE 2AC; SMALL INTERFERING RNA; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GLYCOGEN SYNTHESIS; MALE; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; RAT;

AMYLOID-BETA; DONEPEZIL; GSK-3Β; NACHRS; NEUROPROTECTION; PP2A;

AMYLOID BETA-PEPTIDES; ANIMALS; FEMALE; GLYCOGEN SYNTHASE KINASE 3; INDANS; MALE; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PIPERIDINES; PROTEIN PHOSPHATASE 2; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC;

EID: 84887054237     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12319     Document Type: Article

References (46)

1. Akaike A., Takada-Takatori Y., Kume T., and, Izumi Y., (2010) Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection. J. Mol. Neurosci. 40, 211-216.
2. Akasofu S., Kosasa T., Kimura M., and, Kubota A., (2003) Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation. Eur. J. Pharmacol. 472, 57-63.
3. Arias E., Gallego-Sandin S., Villarroya M., Garcia A. G., and, Lopez M. G., (2005) Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J. Pharmacol. Exp. Ther. 315, 1346-1353.
4. Chen L. J., Wang Y. J., and, Tseng G. F., (2010) Compression alters kinase and phosphatase activity and tau and MAP2 phosphorylation transiently while inducing the fast adaptive dendritic remodeling of underlying cortical neurons. J. Neurotrauma 27, 1657-1669.
5. Del Barrio L., Martin-de-Saavedra M. D., Romero A., Parada E., Egea J., Avila J., McIntosh J. M., Wonnacott S., and, Lopez M. G., (2011) Neurotoxicity induced by okadaic acid in the human neuroblastoma SH-SY5Y line can be differentially prevented by alpha7 and beta2* nicotinic stimulation. Toxicol. Sci. 123, 193-205.
6. Eichhorn P. J., Creyghton M. P., and, Bernards R., (2009) Protein phosphatase 2A regulatory subunits and cancer. Biochim. Biophys. Acta 1795, 1-15.
7. Farrimond L. E., Roberts E., and, McShane R., (2012) Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ open 2, e000917.
8. Gauthier S., and, Molinuevo J. L., (2013) Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. Alzheimers Dement. 9, 326-331.
9. Gong C. X., Grundke-Iqbal I., and, Iqbal K., (1994) Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A. Neuroscience 61, 765-772.
10. Gong C. X., Lidsky T., Wegiel J., Zuck L., Grundke-Iqbal I., and, Iqbal K., (2000) Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. J. Biol. Chem. 275, 5535-5544.
11. Hashiguchi M., and, Hashiguchi T., (2013) Kinase-kinase interaction and modulation of tau phosphorylation. Int. Rev. Cell Mol. Biol. 300, 121-160.
12. Hashimoto M., Kazui H., Matsumoto K., Nakano Y., Yasuda M., and, Mori E., (2005) Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am. J. Psychiatry 162, 676-682.
13. Hsu M. J., Hsu C. Y., Chen B. C., Chen M. C., Ou G., and, Lin C. H., (2007) Apoptosis signal-regulating kinase 1 in amyloid beta peptide-induced cerebral endothelial cell apoptosis. J. Neurosci. 27, 5719-5729.
14. Janssens V., and, Goris J., (2001) Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J. 353, 417-439.
15. Koh S. H., Kim S. H., Kwon H., et al,. (2003) Epigallocatechin gallate protects nerve growth factor differentiated PC12 cells from oxidative-radical- stress-induced apoptosis through its effect on phosphoinositide 3-kinase/Akt and glycogen synthase kinase-3. Brain Res. Mol. Brain Res. 118, 72-81.
16. Koh S. H., Noh M. Y., and, Kim S. H., (2007) Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. Brain Res. 10, 254-262.
17. Kosik K. S., (1992) Cellular aspects of Alzheimer neurofibrillary pathology. Prog. Clin. Biol. Res. 379, 183-193.
18. Lahmy V., Meunier J., Malmstrom S., Naert G., Givalois L., Kim S. H., Villard V., Vamvakides A., and, Maurice T., (2013) Blockade of tau hyperphosphorylation and Abeta generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and sigma receptor agonist, in a nontransgenic mouse model of Alzheimer's disease. Neuropsychopharmacology. in press.
19. Lechward K., Awotunde O. S., Swiatek W., and, Muszynska G., (2001) Protein phosphatase 2A: variety of forms and diversity of functions. Acta Biochim. Pol. 48, 921-933.
20. Lee Y. I., Seo M., Kim Y., Kim S. Y., Kang U. G., Kim Y. S., and, Juhnn Y. S., (2005) Membrane depolarization induces the undulating phosphorylation/dephosphorylation of glycogen synthase kinase 3beta, and this dephosphorylation involves protein phosphatases 2A and 2B in SH-SY5Y human neuroblastoma cells. J. Biol. Chem. 280, 22044-22052.
21. Leyhe T., Hoffmann N., Stransky E., and, Laske C., (2009) Increase of SCF plasma concentration during donepezil treatment of patients with early Alzheimer's disease. Int. J. Neuropsychopharmacol. 12, 1319-1326.
22. Lim Y. W., Yoon S. Y., Choi J. E., Kim S. M., Lee H. S., Choe H., Lee S. C., and, Kim D. H., (2010) Maintained activity of glycogen synthase kinase-3beta despite of its phosphorylation at serine-9 in okadaic acid-induced neurodegenerative model. Biochem. Biophys. Res. Commun. 395, 207-212.
23. Liu R., and, Wang J. Z., (2009) Protein phosphatase 2A in Alzheimer's disease. Pathophysiology 16, 273-277.
24. Liu F., Grundke-Iqbal I., Iqbal K., and, Gong C. X., (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci. 22, 1942-1950.
25. Longin S., Jordens J., Martens E., et al,. (2004) An inactive protein phosphatase 2A population is associated with methylesterase and can be re-activated by the phosphotyrosyl phosphatase activator. Biochem. J. 380, 111-119.
26. Min D., Mao X., Wu K., et al,. (2012) Donepezil attenuates hippocampal neuronal damage and cognitive deficits after global cerebral ischemia in gerbils. Neurosci. Lett. 510, 29-33.
27. Noh M. Y., Koh S. H., Kim Y., Kim H. Y., Cho G. W., and, Kim S. H., (2009) Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-beta-induced neuronal cell death. J. Neurochem. 108, 1116-1125.
28. Park S. S., Jung H. J., Kim Y. J., Park T. K., Kim C., Choi H., Mook-Jung I. H., Koo E. H., and, Park S. A., (2012) Asp664 cleavage of amyloid precursor protein induces tau phosphorylation by decreasing protein phosphatase 2A activity. J. Neurochem. 123, 856-865.
29. Picciotto M. R., and, Zoli M., (2008) Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Front. Biosci. 13, 492-504.
30. Plattner F., Angelo M., and, Giese K. P., (2006) The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem. 281, 25457-25465.
31. Qian W., Shi J., Yin X., Iqbal K., Grundke-Iqbal I., Gong C. X., and, Liu F., (2010) PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J. Alzheimers Dis. 19, 1221-1229.
32. Selkoe D. J., (2004) Alzheimer disease: mechanistic understanding predicts novel therapies. Ann. Intern. Med. 140, 627-638.
33. Shen H., Kihara T., Hongo H., Wu X., Kem W. R., Shimohama S., Akaike A., Niidome T., and, Sugimoto H., (2010) Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of alpha7 nicotinic receptors and internalization of NMDA receptors. Br. J. Pharmacol. 161, 127-139.
34. Sontag E., Nunbhakdi-Craig V., Sontag J. M., Diaz-Arrastia R., Ogris E., Dayal S., Lentz S. R., Arning E., and, Bottiglieri T., (2007) Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J. Neurosci. 27, 2751-2759.
35. Sugimoto H., Iimura Y., Yamanishi Y., and, Yamatsu K., (1995) Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J. Med. Chem. 38, 4821-4829.
36. Takada Y., Yonezawa A., Kume T., Katsuki H., Kaneko S., Sugimoto H., and, Akaike A., (2003) Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J. Pharmacol. Exp. Ther. 306, 772-777.
37. Takada-Takatori Y., Kume T., Sugimoto M., Katsuki H., Sugimoto H., and, Akaike A., (2006) Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 51, 474-486.
38. Takada-Takatori Y., Kume T., Ohgi Y., Izumi Y., Niidome T., Fujii T., Sugimoto H., and, Akaike A., (2008) Mechanism of neuroprotection by donepezil pretreatment in rat cortical neurons chronically treated with donepezil. J. Neurosci. Res. 86, 3575-3583.
39. Vale C., and, Botana L. M., (2008) Marine toxins and the cytoskeleton: okadaic acid and dinophysistoxins. FEBS J. 275, 6060-6066.
40. Wang J., Tung Y. C., Wang Y., Li X. T., Iqbal K., and, Grundke-Iqbal I., (2001) Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. FEBS Lett. 507, 81-87.
41. Wang J. Z., Grundke-Iqbal I., and, Iqbal K., (2007) Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur. J. Neurosci. 25, 59-68.
42. Xing Y., Li Z., Chen Y., Stock J. B., Jeffrey P. D., and, Shi Y., (2008) Structural mechanism of demethylation and inactivation of protein phosphatase 2A. Cell 133, 154-163.
43. Yin K. J., Hsu C. Y., Hu X. Y., Chen H., Chen S. W., Xu J., and, Lee J. M., (2006) Protein phosphatase 2A regulates bim expression via the Akt/FKHRL1 signaling pathway in amyloid-beta peptide-induced cerebrovascular endothelial cell death. J. Neurosci. 26, 2290-2299.
44. Zhang C. E., Tian Q., Wei W., Peng J. H., Liu G. P., Zhou X. W., Wang Q., Wang D. W., and, Wang J. Z., (2008) Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus. Neurobiol. Aging 29, 1654-1665.
45. Zhou X. W., Gustafsson J. A., Tanila H., Bjorkdahl C., Liu R., Winblad B., and, Pei J. J., (2008) Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A. Neurobiol. Dis. 31, 386-394.
46. Zhou X. W., Winblad B., Guan Z., and, Pei J. J., (2009) Interactions between glycogen synthase kinase 3beta, protein kinase B, and protein phosphatase 2A in tau phosphorylation in mouse N2a neuroblastoma cells. J. Alzheimers Dis. 17, 929-937.